Jump to content

Nonsense-mediated decay

From Wikipedia, the free encyclopedia
(Redirected from Nonsense mediated decay)

Canonical NMD pathway (in humans)

Nonsense-mediated mRNA decay (NMD) is a surveillance pathway that exists in all eukaryotes. Its main function is to reduce errors in gene expression by eliminating mRNA transcripts that contain premature stop codons.[1] Translation of these aberrant mRNAs could, in some cases, lead to deleterious gain-of-function or dominant-negative activity of the resulting proteins.[2]

NMD was first described in human cells and in yeast almost simultaneously in 1979. This suggested broad phylogenetic conservation and an important biological role of this intriguing mechanism.[3] NMD was discovered when it was realized that cells often contain unexpectedly low concentrations of mRNAs that are transcribed from alleles carrying nonsense mutations.[4] Nonsense mutations code for a premature stop codon which causes the protein to be shortened. The truncated protein may or may not be functional, depending on the severity of what is not translated. In human genetics, NMD has the possibility to not only limit the translation of abnormal proteins, but it can occasionally cause detrimental effects in specific genetic mutations.[5]

NMD functions to regulate numerous biological functions in a diverse range of cells, including the synaptic plasticity of neurons which may shape adult behavior.[6]

Pathway

[edit]

While many of the proteins involved in NMD are not conserved between species, in Saccharomyces cerevisiae (yeast), there are three main factors in NMD: UPF1, UPF2 and UPF3 (UPF3A and UPF3B in humans), that make up the conserved core of the NMD pathway.[7] All three of these factors are trans-acting elements called up-frameshift (UPF) proteins. In mammals, UPF2 and UPF3 are part of the exon-exon junction complex (EJC) bound to mRNA after splicing along with other proteins, eIF4AIII, MLN51, and the Y14/MAGOH heterodimer, which also function in NMD. UPF1 phosphorylation is controlled by the proteins SMG-1, SMG-5, SMG-6 and SMG-7.

The process of detecting aberrant transcripts occurs during translation of the mRNA. A popular model for the detection of aberrant transcripts in mammals suggests that during the first round of translation, the ribosome removes the exon-exon junction complexes bound to the mRNA after splicing occurs. If after this first round of translation, any of these proteins remain bound to the mRNA, NMD is activated. Exon-exon junction complexes located downstream of a stop codon are not removed from the transcript because the ribosome is released before reaching them. Termination of translation leads to the assembly of a complex composed of UPF1, SMG1 and the release factors, eRF1 and eRF3, on the mRNA. If an EJC is left on the mRNA because the transcript contains a premature stop codon, then UPF1 comes into contact with UPF2 and UPF3, triggering the phosphorylation of UPF1. In vertebrates, the location of the last exon-junction complex relative to the termination codon usually determines whether the transcript will be subjected to NMD or not. If the termination codon is downstream of or within about 50 nucleotides of the final exon-junction complex then the transcript is translated normally. However, if the termination codon is further than about 50 nucleotides upstream of any exon-junction complexes, then the transcript is down regulated by NMD.[8] The phosphorylated UPF1 then interacts with SMG-5, SMG-6 and SMG-7, which promote the dephosphorylation of UPF1. SMG-7 is thought to be the terminating effector in NMD, as it accumulates in P-bodies, which are cytoplasmic sites for mRNA decay. In both yeast and human cells, the major pathway for mRNA decay is initiated by the removal of the 5’ cap followed by degradation by XRN1, an exoribonuclease enzyme. The other pathway by which mRNA is degraded is by deadenylation from 3’-5'.

In addition to the well recognized role of NMD in removing aberrant transcripts, there are transcripts that contain introns within their 3' untranslated regions (UTRs).[9] These messages are predicted to be NMD-targets yet they (e.g., activity-regulated cytoskeleton-associated protein, known as Arc) can play crucial biologic functions suggesting that NMD may have physiologically relevant roles.[9]

Molecular rules governing efficiency

[edit]

NMD is a cellular mechanism that degrades mRNAs containing premature termination codons (PTCs), which can arise from mutations. Comprehensive analyses large scale genetics and gene expression datasets have enabled the systemic identification of the complex rules governing NMD efficiency, and quantification of their relative importance and effect size.[10] This revealed that the efficiency of NMD in recognizing and degrading these faulty transcripts is influenced by several molecular features:

  1. EJC model: The standard EJC model posits that NMD is typically triggered when a PTC is located upstream of the last exon junction complex. If the PTC is downstream of the last EJC, NMD is often inefficient.
  2. Start-proximal effect: PTCs located near the start codon can evade NMD. This evasion is associated with the presence of downstream in-frame stop codons, which can allow the ribosome to bypass the PTC and continue translation.
  3. Exon length and distance to normal stop codon: Long exons and large distances between the PTC and the normal stop codon are associated with inefficient NMD. This suggests that the spatial configuration of the mRNA can influence the accessibility of NMD machinery.
  4. mRNA turnover rate: Transcripts with rapid turnover rates tend to attenuate the effects of NMD. This means that mRNAs that are quickly degraded by other mechanisms may not be efficiently targeted by NMD.
  5. RNA-binding protein motifs: Certain RNA-binding protein motifs near the PTC or within the 3′UTR can modulate NMD efficiency. These motifs can either enhance or inhibit the recognition of PTCs by NMD machinery, depending on their specific interactions with NMD factors.

Mutations

[edit]

Although nonsense-mediated mRNA decay reduces nonsense codons, mutations can occur that lead to various health problems and diseases in humans. A dominant-negative or deleterious gain-of-function mutation can occur if premature terminating (nonsense) codons are translated. NMD is becoming increasingly evident in the way it modifies phenotypic consequences because of the broad way it controls gene expression. For instance, the blood disorder Beta thalassemia is inherited and caused by mutations within the upstream region of the β-globin gene.[11] An individual carrying only one affected allele will have no or extremely low levels of the mutant β-globin mRNA. An even more severe form of the disease can occur called thalassemia intermedia or ‘inclusion body’ thalassemia. Instead of decreased mRNA levels, a mutant transcript produces truncated β chains, which in turn leads to a clinical phenotype in the heterozygote.[11] Nonsense-mediated decay mutations can also contribute to Marfan syndrome. This disorder is caused by mutations in the fibrillin 1 (FBN1) gene and is resulted from a dominant negative interaction between mutant and wild-type fibrillin-1 gene.[11]

Regulating immunogenic frameshift-derived antigens

[edit]

NMD plays a role in the regulation of immunogenic frameshift-derived antigens. Frameshift mutations often result in the production of aberrant proteins that can be recognized as neoantigens by the immune system, particularly in cancer cells.[12] However, frameshift mutations often lead to the translation of an out-of-frame PTC that can activate NMD to degrade these mutant mRNAs before they are translated into proteins, thereby reducing the presentation of these potentially immunogenic peptides on the cell surface via HLA class I molecules. This modulation of immunogenicity means that frameshift-derived neoantigens only contribute to the response to immune checkpoint inhibition if they arise from mutations in parts of the genome that are not recognized by NMD.[13]

Research applications

[edit]

This pathway has a significant effect in the way genes are translated, restricting the amount of gene expression. It is still a new field in genetics, but its role in research has already led scientists to uncover numerous explanations for gene regulation. Studying nonsense-mediated decay has allowed scientists to determine the causes for certain heritable diseases and dosage compensation in mammals.

Heritable diseases

[edit]

The proopiomelanocortin gene (POMC) is expressed in the hypothalamus, in the pituitary gland. It yields a range of biologically active peptides and hormones and undergoes tissue-specific posttranslational processing to yield a range of biologically active peptides producing adrenocorticotropic hormone (ACTH), b-endorphin, and a-, b- and c-melanocyte-stimulating hormone (MSH).[citation needed] These peptides then interact with different melanocortin receptors (MCRs) and are involved in a wide range of processes including the regulation of body weight (MC3R and MC4R), adrenal steroidogenesis (MC2R) and hair pigmentation (MC1R).[14] Published in the British Associations of Dermatologists in 2012, Lack of red hair phenotype in a North-African obese child homozygous for a novel POMC null mutation showed nonsense-mediated decay RNA evaluation in a hair pigment chemical analysis. They found that inactivating the POMC gene mutation results in obesity, adrenal insufficiency, and red hair. This has been seen in both in humans and mice. In this experiment they described a 3-year-old boy from Rome, Italy. He was a source of focus because he had Addison's disease and early onset obesity. They collected his DNA and amplified it using PCR. Sequencing analysis revealed a homozygous single substitution determining a stop codon. This caused an aberrant protein and the corresponding amino acid sequence indicated the exact position of the homozygous nucleotide. The substitution was localized in exon 3 and nonsense mutation at codon 68. The results from this experiment strongly suggest that the absence of red hair in non-European patients with early onset obesity and hormone deficiency does not exclude the occurrence of POMC mutations.[14] By sequencing the patients DNA they found that this novel mutation has a collection of symptoms because of a malfunctioning nonsense-mediated mRNA decay surveillance pathway.

Dosage compensation

[edit]

There has been evidence that the nonsense-mediated mRNA decay pathway participates in X chromosome dosage compensation in mammals. In higher eukaryotes with dimorphic sex chromosomes, such as humans and fruit flies, males have one X chromosome, whereas females have two. These organisms have evolved a mechanism that compensates not only for the different number of sex chromosomes between the two sexes, but also for the differing X/autosome ratios.[15] In this genome-wide survey, the scientists found that autosomal genes are more likely to undergo nonsense-mediated decay than X-linked genes. This is because NMD fine tunes X chromosomes and it was demonstrated by inhibiting the pathway. The results were that balanced gene expression between X and autosomes gene expression was decreased by 10–15% no matter the method of inhibition. The NMD pathway is skewed towards depressing expression of larger population or autosomal genes than x-linked ones. In conclusion, the data supports the view that the coupling of alternative splicing and NMD is a pervasive means of gene expression regulation.[15]

Designing CRISPR-Cas9 experiments

[edit]

The implications of NMD are significant when designing CRISPR-Cas9 experiments, particularly those aimed at gene inactivation.[16] CRISPR-Cas9 introduces double-strand breaks that can lead to insertions or deletions (indels), often resulting in frameshift mutations and PTCs. If these PTCs are located in regions that trigger NMD, the resulting mRNAs will be rapidly degraded, leading to effective gene knockdown. However, if the PTCs are in regions that evade NMD, the mutant mRNAs may be translated into truncated proteins, potentially retaining partial function and leading to incomplete gene inactivation.[13][17] Therefore, understanding and incorporating NMD rules into the design of single guide RNAs (sgRNAs) is essential for achieving desired outcomes in CRISPR-Cas9 experiments. Tools such as NMDetective[13] can predict the likelihood of NMD triggering based on the location of PTCs, thereby aiding in the design of more effective gene-editing strategies.

See also

[edit]

References

[edit]
  1. ^ Baker KE, Parker R (June 2004). "Nonsense-mediated mRNA decay: terminating erroneous gene expression". Current Opinion in Cell Biology. 16 (3): 293–299. doi:10.1016/j.ceb.2004.03.003. PMID 15145354.
  2. ^ Chang YF, Imam JS, Wilkinson MF (2007). "The nonsense-mediated decay RNA surveillance pathway". Annual Review of Biochemistry. 76: 51–74. doi:10.1146/annurev.biochem.76.050106.093909. PMID 17352659. S2CID 2624255.
  3. ^ Kulozik A. "Research Focus 1: Nonsense Mediated Decay (NMD)". Molecular Medicine Partnership Unit. University of Heidelberg. Archived from the original on 2016-11-17. Retrieved 2014-11-17.
  4. ^ Sharma J, Keeling KM, Rowe SM (August 2020). "Pharmacological approaches for targeting cystic fibrosis nonsense mutations". European Journal of Medicinal Chemistry. 200: 112436. doi:10.1016/j.ejmech.2020.112436. PMC 7384597. PMID 32512483.
  5. ^ Holbrook JA, Neu-Yilik G, Hentze MW, Kulozik AE (August 2004). "Nonsense-mediated decay approaches the clinic". Nature Genetics. 36 (8): 801–808. doi:10.1038/ng1403. PMID 15284851. S2CID 23188275.
  6. ^ Notaras M, Allen M, Longo F, Volk N, Toth M, Li Jeon N, et al. (December 2020). "UPF2 leads to degradation of dendritically targeted mRNAs to regulate synaptic plasticity and cognitive function". Molecular Psychiatry. 25 (12): 3360–3379. doi:10.1038/s41380-019-0547-5. PMC 7566522. PMID 31636381. S2CID 204812259.
  7. ^ Behm-Ansmant I, Izaurralde E (February 2006). "Quality control of gene expression: a stepwise assembly pathway for the surveillance complex that triggers nonsense-mediated mRNA decay". Genes & Development. 20 (4): 391–398. doi:10.1101/gad.1407606. PMID 16481468.
  8. ^ Lewis BP, Green RE, Brenner SE. 2003. Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proceedings of the National Academy of Sciences of the United States of America 100:189-192. doi:10.1016/j.bbrc.2009.04.021
  9. ^ a b Bicknell AA, Cenik C, Chua HN, Roth FP, Moore MJ (December 2012). "Introns in UTRs: why we should stop ignoring them". BioEssays. 34 (12): 1025–1034. doi:10.1002/bies.201200073. PMID 23108796. S2CID 5808466.
  10. ^ Lindeboom RG, Supek F, Lehner B (October 2016). "The rules and impact of nonsense-mediated mRNA decay in human cancers". Nature Genetics. 48 (10): 1112–1118. doi:10.1038/ng.3664. PMC 5045715. PMID 27618451.
  11. ^ a b c Frischmeyer PA, Dietz HC (1999). "Nonsense-mediated mRNA decay in health and disease". Human Molecular Genetics. 8 (10): 1893–1900. doi:10.1093/hmg/8.10.1893. PMID 10469842.
  12. ^ Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, et al. (August 2017). "Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis". The Lancet. Oncology. 18 (8): 1009–1021. doi:10.1016/S1470-2045(17)30516-8. PMID 28694034.
  13. ^ a b c Lindeboom RG, Vermeulen M, Lehner B, Supek F (November 2019). "The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy". Nature Genetics. 51 (11): 1645–1651. doi:10.1038/s41588-019-0517-5. PMC 6858879. PMID 31659324.
  14. ^ a b Cirillo G, Marini R, Ito S, Wakamatsu K, Scianguetta S, Bizzarri C, et al. (December 2012). "Lack of red hair phenotype in a North-African obese child homozygous for a novel POMC null mutation: nonsense-mediated decay RNA evaluation and hair pigment chemical analysis". The British Journal of Dermatology. 167 (6): 1393–5. doi:10.1111/j.1365-2133.2012.11060.x. PMID 22612534.
  15. ^ a b Yin S, Deng W, Zheng H, Zhang Z, Hu L, Kong X (June 2009). "Evidence that the nonsense-mediated mRNA decay pathway participates in X chromosome dosage compensation in mammals". Biochemical and Biophysical Research Communications. 383 (3): 378–82. doi:10.1016/j.bbrc.2009.04.021. PMID 19364502.
  16. ^ Popp MW, Maquat LE (June 2016). "Leveraging Rules of Nonsense-Mediated mRNA Decay for Genome Engineering and Personalized Medicine". Cell. 165 (6): 1319–1322. doi:10.1016/j.cell.2016.05.053. PMC 4924582. PMID 27259145.
  17. ^ Smits AH, Ziebell F, Joberty G, Zinn N, Mueller WF, Clauder-Münster S, et al. (November 2019). "Biological plasticity rescues target activity in CRISPR knock outs". Nature Methods. 16 (11): 1087–1093. doi:10.1038/s41592-019-0614-5. PMID 31659326.

Further reading

[edit]
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nonsense-mediated_decay&oldid=1240766160"